Asparkam-L, 5 ml, 10 pcs.

1 ml of solution for intravenous administration contains:

active ingredients:

magnesium asparaginate anhydrous 40 mg (magnesium content - 3.37 mg),

potassium asparaginate anhydrous 45.2 mg (potassium content - 10.33 mg);

Excipients:

sorbitol (sorbitol),

water for injections.

The mechanism of action of the drug Asparkam is associated with the effective participation of L-asparaginate in the transport of magnesium and potassium ions into the intracellular space. Magnesium activates sodium-potassium-ATPase, removing sodium ions from the cell and returning potassium ions; reduces the concentration of sodium and prevents its exchange for calcium in vascular smooth muscles, lowering their resistance. Potassium stimulates the synthesis of ATP, glycogen, proteins, acetylcholine, etc.

Both ions support the polarization of cell membranes.

The drug regulates the conduction of impulses along nerve fibers, synaptic transmission, muscle contraction, the work of the heart muscle. Due to magnesium ions, it participates in the processes of energy intake and consumption, normalizes membrane permeability, neuromuscular conduction, DNA and RNA synthesis, cell growth, cell division, oxygen assimilation and phosphate synthesis.

• To eliminate the deficiency of potassium and magnesium;
• as an aid for various manifestations of coronary heart disease, including acute myocardial infarction;
• chronic circulatory failure;
• heart rhythm disturbances (arrhythmias caused by an overdose of cardiac glycosides).

• Hypersensitivity to the drug Asparkam,
• hyperkalemia,
• hypermagnesemia,
• acute and chronic renal failure,
• insufficiency of the adrenal cortex,
• atrioventricular block II and III degree,
• cardiogenic shock,
• oliguria - anuria,
• acute metabolic acidosis,
• severe myasthenia gravis,
• dehydration, Addison's disease,
• arterial hypotension,
• pregnancy,
• lactation period,
• age up to 18 years (efficacy and safety have not been established).

• Possible nausea, dizziness,
• redness of the face
• thirst,
• lowering blood pressure, hyporeflexia.
• hyperkalemia (nausea, vomiting, diarrhea, paresthesia) and hypermagnesemia (hyperemia of the facial skin, thirst, bradycardia, decreased blood pressure, muscle weakness, fatigue, paresis, coma, areflexia, respiratory depression, convulsions);
• with parenteral administration - atrioventricular block, paradoxical reaction (increase in the number of extrasystoles), phlebitis.
• with rapid intravenous administration, all symptoms of hyperkalemia and hypermagnesemia may appear.

Potassium-sparing diuretics (triamterene, spironolactone), beta-blockers, cyclosporine, heparin, angiotensin-converting enzyme inhibitors, nonsteroidal anti-inflammatory drugs - the risk of hyperkalemia up to the development of arrhythmia and asystole.

Eliminates hypokalemia caused by glucocorticosteroids.

Reduces the undesirable effects of cardiac glycosides.

Due to the content of magnesium ions, it reduces the effect of neomycin, polymyxin B, tetracycline and streptomycin.

Anesthetics increase the inhibitory effect of magnesium on the central nervous system.

It can enhance the neuromuscular blockade caused by depolarizing muscle relaxants (atracuria besylate, decametonium bromide, suxamethonium (chloride, bromide, iodide)).

Calcitriol increases the concentration of magnesium in the blood plasma, calcium preparations reduce the effect of magnesium.

The solution is pharmaceutically compatible with solutions of cardiac glycosides (improves their tolerance).

The drug is administered intravenously (drip or jet). The dose of the drug is determined individually, depending on the indications for use.

Intravenous drip is injected at a rate of 25 drops in 1 minute 1-2 times a day for 10-20 ml (1-2 ampoules of 10 ml or 2-4 ampoules of 5 ml), diluted in 100-200 ml of isotonic sodium chloride solution or 5% glucose solution.

For jet injection, the contents of 1 ampoule of 10 ml or 2 ampoules of 5 ml are diluted in 20 ml of sterile water for injection or 5% glucose solution and injected slowly (no more than 5 ml per minute) into a vein.

Symptoms: hyperkalemia and hypermagnesemia.

Treatment: intravenous calcium chloride; if necessary, hemodialysis and peritoneal dialysis.

No studies have been conducted to assess the effect of the drug on the ability to drive vehicles and engage in other potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.